Published in J Infect Dis on September 01, 2008
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology (2009) 2.10
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut (2010) 1.77
HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis (2012) 1.47
An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis (2013) 1.42
Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol (2009) 1.41
Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis (2011) 1.32
Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS (2009) 1.28
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis (2012) 1.14
Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol (2011) 1.10
Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis (2011) 1.04
Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc (2011) 1.03
Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis (2013) 1.02
HIV and liver disease forum: conference proceedings. Hepatology (2007) 0.93
The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. J Gen Virol (2011) 0.92
Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis (2013) 0.90
Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis (2012) 0.88
Estimating acute viral hepatitis infections from nationally reported cases. Am J Public Health (2014) 0.87
Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care. Clin Infect Dis (2014) 0.86
Differences in hepatitis C virus prevalence and clearance by mode of acquisition among men who have sex with men. J Viral Hepat (2013) 0.85
National Trend and Characteristics of Acute Hepatitis C among HIV-Infected Individuals: A Matched Case-Control Study-Taiwan, 2001-2014. PLoS One (2015) 0.84
Acute hepatitis C outbreak among HIV-infected men, Madrid, Spain. Emerg Infect Dis (2011) 0.84
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol (2013) 0.84
HIV-infected men who have sex with men who identify themselves as belonging to subcultures are at increased risk for hepatitis C infection. PLoS One (2013) 0.83
Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men. Clin Infect Dis (2012) 0.82
Gaining greater insight into HCV emergence in HIV-infected men who have sex with men: the HEPAIG Study. PLoS One (2011) 0.82
Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. J Neurovirol (2011) 0.82
Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study. PLoS One (2014) 0.80
Liver pathology of hepatitis C, beyond grading and staging of the disease. World J Gastroenterol (2016) 0.76
Treatment optimization for HIV/HCV co-infected patients. Ther Adv Infect Dis (2016) 0.75
Profound jaundice in a patient with acute hepatitis C. BMJ Case Rep (2013) 0.75
Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat (2017) 0.75
Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. Curr Epidemiol Rep (2017) 0.75
Incidence of Hepatitis C Virus Infection in the Human Immunodeficiency Virus Outpatient Study Cohort, 2000-2013. Open Forum Infect Dis (2017) 0.75
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) (1995) 3.85
Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology (2002) 2.18
Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med (1997) 2.03
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology (1989) 1.33
Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology (2006) 1.30
Scoring of chronic hepatitis. Clin Liver Dis (2002) 1.25
Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol (2001) 1.20
Acute hepatitis C: a multifaceted disease. Semin Liver Dis (2005) 1.20
Natural history of acute hepatitis C. J Gastroenterol Hepatol (2000) 0.94
The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis (2006) 0.93
Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients. Nephrol Dial Transplant (1998) 0.89
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev (2013) 2.96
HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest (2003) 2.89
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology (2004) 2.54
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol (2004) 2.36
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol (2004) 2.12
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (2006) 2.08
Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab (2003) 2.06
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90
Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes (2002) 1.87
Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol (2007) 1.77
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology (2010) 1.70
Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl (2008) 1.68
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U S A (2007) 1.64
Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci (2009) 1.61
Medullary thymic epithelial cell depletion leads to autoimmune hepatitis. J Clin Invest (2013) 1.57
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52
Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery (2004) 1.51
Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology (2009) 1.48
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46
De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Acute HIV seroconversion in a patient receiving pegylated interferon for treatment of hepatitis C. AIDS Read (2003) 1.38
Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1. AIDS Read (2006) 1.38
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol (2008) 1.29
Retracted Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy. Mol Ther (2007) 1.25
Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol (2013) 1.25
Immunohistochemical evidence for hepatic progenitor cells in liver diseases. Liver (2002) 1.23
Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol (2005) 1.21
Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology (2006) 1.20
Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis (2008) 1.18
DNA sequence polymorphisms in a panel of eight candidate bovine imprinted genes and their association with performance traits in Irish Holstein-Friesian cattle. BMC Genet (2010) 1.14
The quasispecies nature and biological implications of the hepatitis C virus. Infect Genet Evol (2009) 1.14
Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions. RNA (2002) 1.13
Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol (2010) 1.11
Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis (2012) 1.08
Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses (2010) 1.08
Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol (2008) 1.08
Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS (2005) 1.08
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig Dis Sci (2004) 1.04
Morphologic features of extrahepatic manifestations of hepatitis C virus infection. Clin Dev Immunol (2012) 1.04
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun (2007) 1.03
Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol (2005) 1.01
Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J Virol (2009) 1.01
Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. J Immunotoxicol (2009) 1.01
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis (2003) 1.00
Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int (2005) 0.99
Increased prooxidant production and enhanced susceptibility to glutathione depletion in HepG2 cells co-expressing HCV core protein and CYP2E1. J Med Virol (2004) 0.99
Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma. Clin Cancer Res (2009) 0.99
Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2005) 0.97
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr (2008) 0.97
HIV and liver diseases: recent clinical advances. Clin Liver Dis (2005) 0.96
Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr (2004) 0.95
Management of chronic hepatitis C virus in patients with HIV. Curr Treat Options Gastroenterol (2005) 0.95
Basal insulin gene expression significantly improves conventional insulin therapy in type 1 diabetic rats. Diabetes (2002) 0.95
Hepatic cavernous hemangioma: underrecognized associated histologic features. Liver Int (2006) 0.95
Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm. J Infect Dis (2013) 0.94
Classical and emerging roles of vitamin D in hepatitis C virus infection. Semin Liver Dis (2011) 0.94
Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res (2011) 0.94
The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch (2010) 0.93
HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next? Clin Infect Dis (2013) 0.93
Adipocyte accumulation of long-chain fatty acids in obesity is multifactorial, resulting from increased fatty acid uptake and decreased activity of genes involved in fat utilization. Obes Surg (2009) 0.93
Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers. Liver (2002) 0.92
Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91